PT-141

Mechanism

Non-selective melanocortin agonist affecting central arousal circuitry.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Desire and arousal research
• Erectile support context
• On-demand dosing

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

approximately 2.7 hours (human, SC) — study. VYLEESI (bremelanotide) FDA prescribing information, section 12.3.

Storage

Reconstituted: Solution (Vyleesi autoinjector, not lyophilized). Store at or below 25C; do not freeze; protect from light. — source. FDA label, Vyleesi (bremelanotide).

In sport (WADA 2026)

Not prohibited. Bremelanotide is FDA-approved (Vyleesi), so S0 does not apply, and it is not named or classed anywhere on the 2026 list. Compounded or research-grade material is a separate purity question, not a list question. the list

The half-life on file is 2.7 h, measured subcutaneously. No dosing schedule could be read from this record, so the curve below is one dose drawn from the moment it is given. Nothing here says how often it is repeated.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Nausea

  Very common (>10%)onset: Within an hourreported reversible

• Facial flushing

  Common (1-10%)onset: Within an hourreported reversible

• Headache

  Common (1-10%)onset: Hoursreported reversible

• Transient blood pressure increase

  Documentedonset: Post-dosereported reversible

Literature on file 11

• human RCT
  Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics & Gynecology 2019, cited 133x) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial (Women's Health 2016, cited 68x) graded on: a randomised trial — “Randomized, Placebo-Controlled Dose-Finding Trial”
• human observational
  Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov. graded on: a synthesis of human studies — “systematic review”
• review or editorial
  The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective. graded on: indexed as "Historical Article" - secondary literature, not a study — “Historical Article”
• review or editorial
  Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• computational
  Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. graded on: a computational prediction — read from the indexed abstract — “in silico”
• human RCT
  NCT02333071: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) graded on: a randomised trial — “Randomized, Double-blind, Placebo-controlled, Trial”
• human RCT
  NCT02338960: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) graded on: a randomised trial — “Randomized, Double-blind, Placebo-controlled, Trial”
• human RCT
  NCT01382719: A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder) graded on: a randomised trial — “Randomized, Parallel Group, Dose-finding Trial”
• human RCT
  FDA approval NDA210557 graded on: an FDA approval (NDA210557), which requires adequate and well-controlled human investigations — “NDA210557”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous agrees with the record

  A dose of 1-2 mg subcutaneously, 45-60 minutes before anticipated activity, is circulated as the standard protocol for both men and women.

  1,000–2,000 mcg (1–2 mg) subcutaneously, 45–60 minutes before anticipated sexual activity.

  On the record The corpus holds 1.75 mg as needed (the VYLEESI approved dose, NDA210557, approved 2019-06-21 for HSDD in premenopausal women). The circulated range brackets the approved dose but extends above it, and the approval covers neither men nor a 2 mg dose.

  Source 1

• unverified community data timing common agrees with the record

  A ceiling of no more than one dose in 24 hours and eight doses per month circulates, taken directly from the Vyleesi label.

  no more than 8 doses per month

  On the record The corpus dosing row holds 1.75 mg as needed without the label's frequency caps. The circulated caps are the FDA label's own; the record does not carry them.

  Source 1

• unverified community data side effect common agrees with the record

  It is circulated that nausea occurred in about 40% of trial participants and is the most common side effect.

  Nausea is the most common side effect (40% in clinical trials).

  On the record The corpus records nausea as "Very common (>10%)", onset within an hour, reversible. The 40% figure is consistent with the trial literature band the record summarises.

  Source 1

• unverified community data benefit common nothing on file either way

  Off-label use in men for erectile dysfunction, including non-responders to sildenafil, is circulated as an established application at the same 1-2 mg dose.

  one of the few sexual health treatments effective in both men and women

  On the record The corpus benefits list includes "Erectile support context", and intranasal bremelanotide was studied in men in early trials — but the approval is for HSDD in women only, and no approved or trial-verified male subcutaneous dose is on file. The community reuses the female HSDD dose for men without a record supporting it.

  Source 1

Identity

PubChem CID 9941379 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 9941379, the identifier on this record.

Molecular weight

1025.2

Molecular formula

C50H68N14O10

CAS number

189691-06-3

PubChem CID

9941379

InChI key

FFHBJDQSGDNCIV-MFVUMRCOSA-N

Sequence

XDHFRWK

SMILES

CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C

InChI

InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1

Classified as

Melanocortin Receptor Agonismmechanism

A record listing only melanocortin agonism with no receptor subtype is underspecified. Pigmentation, appetite and arousal come from different receptors, so a claim graded for one says nothing about the others.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• PT-141
• Bremelanotide (PT-141)

Listed prices 237

What 184 shops we track listed for PT-141, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record